James I Hagadorn1,2, Elizabeth A Brownell1,2, Jennifer M Trzaski1,2, Kendall R Johnson1,2, Shabnam Lainwala1,2, Brendan T Campbell3, Katherine W Herbst4. 1. Division of Neonatology, Connecticut Children's Medical Center, Hartford, Connecticut. 2. Department of Pediatrics, University of Connecticut School of Medicine, Farmington, Connecticut. 3. Department of Pediatric Surgery, Connecticut Children's Medical Center, Hartford, Connecticut. 4. Divisions of Pediatric Urology and Nephrology, and Department of Research, Connecticut Children's Medical Center, Hartford, Connecticut.
Abstract
BACKGROUND: We examined recent trends and interhospital variation in use of indomethacin, ibuprofen, and surgical ligation for patent ductus arteriosus (PDA) in very-low-birth-weight (VLBW) infants. METHODS: Included in this retrospective study of the Pediatric Hospital Information System database were 13,853 VLBW infants from 19 US children's hospitals, admitted at age < 3 d between 1 January 2005 and 31 December 2014. PDA management and in-hospital outcomes were examined for trends and variation. RESULTS: PDA was diagnosed in 5,719 (42%) VLBW infants. Cyclooxygenase inhibitors and/or ligation were used in 74% of infants with PDA overall, however studied hospitals varied greatly in PDA management. Odds of any cyclooxygenase inhibitor or surgical treatment for PDA decreased 11% per year during the study period. This was temporally associated with improved survival but also with increasing bronchopulmonary dysplasia, periventricular leukomalacia, retinopathy of prematurity, and acute renal failure in unadjusted analyses. There was no detectable correlation between hospital-specific changes in PDA management and hospital-specific changes in outcomes of preterm birth during the study period. CONCLUSION: Use of cyclooxygenase inhibitors and ligation for PDA in VLBW infants decreased over a 10-y period at the studied hospitals. Further evidence is needed to assess the impact of this change in PDA management.
BACKGROUND: We examined recent trends and interhospital variation in use of indomethacin, ibuprofen, and surgical ligation for patent ductus arteriosus (PDA) in very-low-birth-weight (VLBW) infants. METHODS: Included in this retrospective study of the Pediatric Hospital Information System database were 13,853 VLBW infants from 19 US children's hospitals, admitted at age < 3 d between 1 January 2005 and 31 December 2014. PDA management and in-hospital outcomes were examined for trends and variation. RESULTS: PDA was diagnosed in 5,719 (42%) VLBW infants. Cyclooxygenase inhibitors and/or ligation were used in 74% of infants with PDA overall, however studied hospitals varied greatly in PDA management. Odds of any cyclooxygenase inhibitor or surgical treatment for PDA decreased 11% per year during the study period. This was temporally associated with improved survival but also with increasing bronchopulmonary dysplasia, periventricular leukomalacia, retinopathy of prematurity, and acute renal failure in unadjusted analyses. There was no detectable correlation between hospital-specific changes in PDA management and hospital-specific changes in outcomes of preterm birth during the study period. CONCLUSION: Use of cyclooxygenase inhibitors and ligation for PDA in VLBW infants decreased over a 10-y period at the studied hospitals. Further evidence is needed to assess the impact of this change in PDA management.
Authors: Jonathan L Slaughter; Patricia B Reagan; Roopali V Bapat; Thomas B Newman; Mark A Klebanoff Journal: Eur J Pediatr Date: 2016-02-15 Impact factor: 3.183
Authors: Barbara Schmidt; Robin S Roberts; Avroy Fanaroff; Peter Davis; Haresh M Kirpalani; Chuks Nwaesei; Michael Vincer Journal: J Pediatr Date: 2006-06 Impact factor: 4.406
Authors: Dany E Weisz; Lucia Mirea; Erin Rosenberg; Maximus Jang; Linh Ly; Paige T Church; Edmond Kelly; S Joseph Kim; Amish Jain; Patrick J McNamara; Prakesh S Shah Journal: JAMA Pediatr Date: 2017-05-01 Impact factor: 16.193
Authors: Sydney R Rooney; Elaine L Shelton; Ida Aka; Christian M Shaffer; Ronald I Clyman; John M Dagle; Kelli Ryckman; Tamorah R Lewis; Jeff Reese; Sara L Van Driest; Prince J Kannankeril Journal: Pharmacogenomics Date: 2019-08 Impact factor: 2.533
Authors: Nansi S Boghossian; Barbara T Do; Edward F Bell; John M Dagle; Jane E Brumbaugh; Barbara J Stoll; Betty R Vohr; Abhik Das; Seetha Shankaran; Pablo J Sanchez; Myra H Wyckoff; M Bethany Ball Journal: Early Hum Dev Date: 2017-07-08 Impact factor: 2.079
Authors: Megan Barcroft; Christopher McKee; Darren P Berman; Rachel A Taylor; Brian K Rivera; Charles V Smith; Jonathan L Slaughter; Afif El-Khuffash; Carl H Backes Journal: Clin Perinatol Date: 2022-01-21 Impact factor: 3.430
Authors: Shannon E G Hamrick; Hannes Sallmon; Allison T Rose; Diego Porras; Elaine L Shelton; Jeff Reese; Georg Hansmann Journal: Pediatrics Date: 2020-11 Impact factor: 7.124
Authors: Michael L O'Byrne; Marisa E Millenson; Connor B Grady; Jing Huang; Nicolas A Bamat; David A Munson; Lihai Song; Yoav Dori; Matthew J Gillespie; Jonathan J Rome; Andrew C Glatz Journal: Am Heart J Date: 2019-08-17 Impact factor: 4.749